Pediatrics in Review Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


(Pediatrics in Review. 1984;6:73-94.)
© 1984 American Academy of Pediatrics

This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Neonatal Hypoglycemia After Administration of Tocolytic Drugs to Mothers

Tocolytic or beta-sympathomimetic drugs (ritodrine, isoxsuprine, terbutaline, finoterol, salbutamol) are widely used to prevent premature delivery. The drugs are useful because of their rather selective beta-2 effects which produce smooth muscle relaxation. These drugs have been considered relatively safe and the side effects are usually well tolerated; however, increasing reports of associated adverse reactions emphasize the necessity for extreme caution in their use. Serious adverse effects can occur both in mothers and neonates, especially when larger doses are used.

Epstein et al found hypoglycemia in two thirds of babies whose mothers were treated with beta-sympathomimetic drugs. These drugs stimulate cyclic adenosine monophosphate (cAMP), which induces glycogen release and breakdown from the muscles and liver causing an elevation in concentrations of blood glucose and insulin.







HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 1984 by the American Academy of Pediatrics.